Month: March 2026

TORONTO, March 10, 2026 (GLOBE NEWSWIRE) — Summit Royalties Ltd. (TSXV: SUM, OTCQB: SUMMF) (the “Corporation” or “Summit”) announces that it has granted an aggregate of 350,000 restricted share units of the Corporation (“RSUs”) to certain senior officers of the Corporation pursuant to its omnibus incentive plan (the “Plan”). Of the 350,000 RSUs, 175,000 RSUs are scheduled to vest on March 9, 2027 and the remaining 175,000 RSUs are scheduled to vest on March 9, 2028. Once vested, each RSU represents the right to receive one common share in the capital of the Corporation per RSU held, a cash amount equivalent, or a combination thereof, in each case subject to the terms and conditions of the Plan and the applicable RSU agreement. About Summit Royalties Ltd. Summit Royalties Ltd. is a...

 – Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization   – Anticipating initiation of pivotal clinical trial in 2026   – Updated electronics architecture delivers significant improvement in glucose measurement accuracy, with a material reduction in MARD across multi-day wear   – Multimodal sensing platform powered by advanced AI-native analytics to deliver personalized metabolic health insights   – CGM+ next-generation modular device architecture designed to reduce cost and improve sustainability versus current market-leading CGMs  – Company is positioning device to participate in fast-growing $15bn CGM market and adjacent sectors DUBLIN and WILSONVILLE, Ore., March 10, 2026 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage...

Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate. This milestone follows the Company’s previously announced manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S, a leading global GMP CDMO, established to support the supply of clinical trial material for Polyrizon’s clinical development program. The GMP manufacturing milestone represents a key step in Polyrizon’s clinical development program and supports the company’s preparations for a planned clinical study in the United States later this year. The GMP batch was manufactured...

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES10 MARCH 2026 at 13.50 EET          Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026 In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2026 transferred altogether 172,778 Orion Corporation B shares held by the company as a share reward for earning period 2023–2025 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022. After the share transfer, the total number of own B shares held by Orion Corporation is 268,166. Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 10 February 2022. Orion CorporationLiisa Hurme President...

CLAYMONT, DE, March 10, 2026 (GLOBE NEWSWIRE) — Archimedes Tech SPAC Partners III Co. (Nasdaq: ARCIU) (the “Company”) today announced that, commencing March 16, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The ordinary shares and warrants that are separated will trade on The Nasdaq Global Market under the symbols “ARCI” and “ARCIW,” respectively. Those units not separated will continue to trade on The Nasdaq Global Market under the symbol “ARCIU.” Holders of units will need to have their brokers contact Odyssey Transfer and Trust Company, the Company’s transfer agent, in order to separate the units into ordinary...

Veteran Technology Executive Brings Public Company, Capital Markets, and Operating Experience to Support Virtuix’s Growth Strategy AUSTIN, Texas, March 10, 2026 (GLOBE NEWSWIRE) — Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, today announced the appointment of Brett Moyer to the Company’s Board of Directors, effective immediately. Brett Moyer has served as Chief Financial Officer of Datavault AI (NASDAQ), an AI-driven data experience, valuation, and monetization entity since January 2025, and has been a Director and Chairman of the Board since 2010. He was a founding member of WiSA Technologies and served as president, CEO, and director from 2010 until December 2024, when the company acquired Data Vault Holdings’ assets and expanded its operations as Datavault AI. He has also served as a...

DUBLIN, March 10, 2026 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an update on its trading activities for Quarter 4, 2025 and some key business updates. Trading UpdateThe Company expects Quarter 4, 2025 revenue within the range of approximately $11.5 million to $12.5 million. This compares to Quarter 4, 2024 revenue of $15.9 million, which was driven by a substantial increase in TrinScreen™ HIV sales from $0.4 million in Quarter 4, 2023 to $3.2 million in Quarter 4, 2024. The reduction in revenue between Quarter 4, 2024 and Quarter 4, 2025 was primarily driven by:The residual impact of the disruption to the global health market for HIV testing in 2025 due...

LAS VEGAS, March 10, 2026 (GLOBE NEWSWIRE) — VenHub Global, Inc. (NASDAQ: VHUB) (“VenHub” or the “Company”), a leader in fully autonomous Smart Store technology, today announced it has expanded its integration with Stripe, a programmable financial services company, to power a unified payments layer across VenHub’s growing global network of fully robotic Smart Stores. Building on an existing relationship, the expanded collaboration formalizes Stripe as VenHub’s primary payments infrastructure partner for its platform, enabling faster global expansion with seamless, secure, and flexible payment experiences. Stripe will serve as VenHub’s primary payments infrastructure, while allowing flexibility to support retailer- or regional-specific payment requirements. Under this enhanced collaboration, VenHub is rolling out a fully integrated...

With commercialization of its advanced optical engines under way, the Company intends to reveal its latest product advancements to industry leadersBlazar4Channel BlazarSAN JOSE, Calif., March 10, 2026 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company“) (NASDAQ: POET), a leader in the design and implementation of highly-integrated optical engines and light sources for artificial intelligence networks, today announced it plans to perform live demonstrations of its two leading external light source (ELS) products at the annual Optical Fiber Communications (OFC) Conference, which will be held at the Los Angeles Convention Center from March 16-19, 2026. POET’s executive management team and engineers will be meeting customers and industry analysts at the Company’s Booth No. 339 during...

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced additional data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142. The established T1D adult patient cohort demonstrated early signals of C-peptide preservation which aligned with the anticipated mechanism of action of SAB-142. In the T1D cohort (n=6), SAB-142 treated study participants (n=4) showed no decrease in C-peptide levels at Day 120 compared to baseline....